Clinical trials: Macular Degeneration Advanced
Corneal Deformity, Macular Degeneration Advanced
Comparison of Ocular Changes by Surgical Menopause Using Optical Coherence Tomography (OCT)
The aim of this study is to investigate the early changes in macular thickness, corneal thickness and intraocular pressure in young women undergoing surgical menopause.
- Conditions
- Corneal Deformity, Macular Degeneration Advanced, Surgical Menopause
- Trial name
- NCT05920655
- Testing
- Optic coherence tomography
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Batman Training and Research Hospital
Age Related Macular Degeneration
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
The purpose of this first in man study is to examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration.
- Trial name
- GEM (NCT01301443)
- Testing
- Subretinally injected RetinoStat
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Oxford BioMedica
Dry Macular Degeneration, Geographic Atrophy
Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD
The Phase I/IIa clinical trial is designed to assess the feasibility of delivery and safety of Human Embryonic Stem Cell-Derived RPE Cells on a parylene membrane (CPCB-RPE1) in patients with advanced, dry age-related macular…
- Trial name
- NCT02590692
- Testing
- CPCB-RPE1
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Regenerative Patch Technologies, LLC
Dry Age Related Macular Degeneration
The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD
To evaluate the safety and tolerability of human somatic cell nuclear transfer embryonic stem cell derived retinal pigmented epithelial(SCNT-hES-RPE) cellular therapy in patients with advanced dry AMD
- Trial name
- NCT03305029
- Testing
- SCNT-hES-RPE Cells
- Where
- South Korea
- Volunteers
- 3 people
- Sponsor
- CHA University
Age-Related Macular Degeneration, Geographic Atrophy
Sirolimus for Advanced Age-Related Macular Degeneration
This study will determine whether a drug called sirolimus is safe to give to people with geographic atrophy (GA) and if it can help preserve vision in patients.
- Trial name
- SIRGA2 (NCT01445548)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Maculopathy, Age-Related Maculopathies
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration
- Trial name
- NCT01003691
- Testing
- RN6G
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pfizer
Advanced Dry Macular Degeneration
Alpha MSH in Ocular Disease
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease.
- Trial name
- NCT03451578
- Testing
- Alpha MSH assay
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Duke University
Macular Degeneration
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated.
- Trial name
- NCT04002310
- Testing
- BI 754132
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Age-Related Maculopathy
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
- Trial name
- NCT01577381
- Testing
- RN6G
- Where
- 83 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Retinal Vascular Disorder, Macular Degeneration
Ocular Imaging Study Using Advanced OCT
The purpose of this study is to evaluate this AngioScan angiography software on patients with various retinal vascular disorders.
- Trial name
- NCT02827071
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, Los Angeles
Age-related Macular Degeneration
Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).
- Trial name
- NCT01835015
- Testing
- CLG561
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
- Trial name
- OASIS (NCT07660640)
- Testing
- observational study, VOY-101
- Where
- 4 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Macular Degeneration
Lucentis in Advanced Macular Degeneration
Patients with low vision (visual acuity 20/400 or worse) were excluded from the large Phase III ranibizumab clinical trials. It is not known if treatment with ranibizumab results in improved visual function in such patients.Since…
- Trial name
- NCT00896779
- Testing
- ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Steven R. Sanislo
AMD - Age-Related Macular Degeneration, Anxiety
Visual Rehabilitation and Depression in Visually Impaired Patients With AMD
Purpose: The aim of this study is to evaluate the impact of visual rehabilitation in visually impaired patients with advanced AMD by the use of questionnaires on the anxiety and depression status.
- Conditions
- AMD - Age-Related Macular Degeneration, Anxiety, Depression Disorders
- Trial name
- RET 06-24 (NCT06906003)
- Testing
- visual rehabilitation program
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Age-Related Macular Degeneration, Geographic Atrophy
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
- Trial name
- JOURNEY (NCT06087458)
- Testing
- VOY-101
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Von Hippel-Lindau Syndrome
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
This study will examine whether he drug ranibizumab can slow or stop the growth of angiomas (blood vessel tumors) in patients with Von Hippel-Lindau syndrome (VHL).
- Trial name
- NCT00089765
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
The purpose of his study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry Age-Related Macular Degeneration (AMD) from one to five years following the surgical…
- Trial name
- NCT02463344
- Testing
- MA09-hRPE
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Age-Related Macular Degeneration
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation.
- Trial name
- P52901 (NCT01033721)
- Testing
- Palomid 529
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Paloma Pharmaceuticals, Inc.
Dry Age Related Macular Degeneration
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with dry Age Related Macular Degeneration (AMD) and to…
- Trial name
- Dry AMD (NCT01344993)
- Testing
- MA09-hRPE
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Cataract, Macular Degeneration Advanced
Cataract Surgery on Advanced Age Related Macular Degeneration Patients
The degree at which cataract surgery improves visual function in patients with advanced age-related macular degeneration (Advanced AMD) has been an on-going topic of discussion.
- Trial name
- NCT04045704
- Testing
- Cataract Surgery
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of British Columbia